Adrenaline Nasal Spray for Severe Allergic Reactions Approved in UAE

The Emirates Drug Establishment has approved EURneffy, an epinephrine nasal spray developed by ALK Abelló, for the emergency treatment of severe allergic reactions in the UAE. The product is available in 1 mg and 2 mg strengths and can be used by adults and children aged four and above. With the approval, the UAE becomes the first country in the region to authorise an intranasal adrenaline treatment for anaphylaxis.
The spray offers an alternative to injection-based delivery, allowing epinephrine to be administered through the nose. The regulator noted that timely delivery is critical in emergency situations, while injections can present challenges such as needle aversion or difficulty during acute episodes.
Designed for ease of use, the nasal spray enables rapid administration, including by individuals without medical training, with dosing determined based on patient weight.
The approval follows regulatory review and coordination with the manufacturer to facilitate availability in the UAE market.